Prostamax

Bioregulators Research compound (not approved for human use)

Synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Pro) · also known as KEDP, Lys-Glu-Asp-Pro

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

Prostamax is described as the synthetic successor to older prostate tissue extracts from the same research group. Published work is limited to chromatin studies in human lymphocytes and animal models, with no published human clinical trials.

Commonly reported dosing (20 mg vial)

Reconstituted with 2 mL → 10 mg/mL.

Phase	Dose	Volume	U-100 units
Starting	500 mcg	0.05 mL	5
Standard	750 mcg	0.075 mL	7.5
Higher	1 mg	0.1 mL	10

Frequency: Once daily, usually intramuscular with subcutaneous as an alternative (8-12 week courses, community-reported) · Half-life: Not well characterized in the published literature

Open in calculator

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
2 mL of bacteriostatic water is added slowly down the inside wall of the 20 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 10 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: Lyophilized vials are commonly stored frozen (about -20 °C), dry, and protected from light.

After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C), protected from light, and freeze-thaw cycles are commonly avoided.

How it works

Reported in cell studies to loosen condensed chromatin in lymphocytes from older donors; the proposed link to prostate gene expression is hypothesized.

Researched for

Studied in human lymphocytes for chromatin decondensation and sister-chromatid exchange in older donors.
Examined in rat models for effects on prostate inflammation and fibrotic remodeling, per the reference.

Notes

The reference lists intramuscular use as the primary route (with larger needles), unlike most peptides in this batch.
Evidence comes largely from a single research group (Khavinson and colleagues, St. Petersburg), mostly cell-culture and animal work; independent replication and controlled human trials are scarce.
Published human work from the originating group has mostly used oral or other non-vial formats; the vial, reconstitution and dosing figures here reflect community-reported conventions rather than trial-validated regimens.
Not FDA-approved.

Sources

Last reviewed 2026-10-06.

Testagen

Synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Gly)

Testagen is a four-residue peptide (lysine, glutamate, aspartate, glycine) modeled on pituitary extracts, linked in the Khavinson literature to the pituitary-gonadal axis.

20 mg vial · Once daily, subcutaneous (8-12 week courses, community-reported)

Livagen

Synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Ala)

Livagen is a four-residue peptide (lysine, glutamate, aspartate, alanine) studied by the Khavinson group, with a liver-oriented label.

20 mg vial · Once daily, subcutaneous (8-12 week courses, community-reported)

Vesugen

Synthetic tripeptide bioregulator (Lys-Glu-Asp)

Vesugen is a three-residue peptide (lysine, glutamate, aspartate) from the Khavinson family, associated with blood vessels and the cardiovascular system.

20 mg vial · Once daily, subcutaneous (8-12 week courses, community-reported)